Abstract
Tazobactam was shown to be a potent inhibitor of group 1, 2a, 2b, and 2b' beta-lactamases. Extended kinetic studies with class A and C serine beta-lactamases showed that the PC1, TEM-2, and P99 enzymes all were reversibly inhibited prior to inactivation of the enzymes. The CcrA metallo-beta-lactamase was less well inhibited, with a 50% inhibitory concentration at least 3 orders of magnitude less favorable than those for most serine beta-lactamases. The numbers of hydrolytic turnovers of tazobactam before inactivation were 2 for PC1, 125 for TEM-2, 50 for P99, and 4,000 for the CcrA enzyme. In spectral studies, transient intermediates were formed after reaction of tazobactam with the PC1, TEM-2, and CcrA beta-lactamases, corresponding to enzyme-associated intermediates responsible for hydrolysis of tazobactam. Chromophores absorbing at 270 nm (CcrA) and 288 nm (TEM-2 and PC1) were observed for these reaction intermediates. The P99 cephalosporinase formed a stable complex with a UV maximum at 295 nm. Incubation of tazobactam with all of the enzymes resulted in accumulation of a tazobactam reaction product with a short-wavelength absorbance. This product has characteristics similar to those of the major eucaryotic metabolite of tazobactam. Possible reaction mechanisms are presented to explain the findings. In conclusion, both serine-based and metallo-beta-lactamases were irreversibly inactivated by tazobactam following an initial transient inhibition phase.
Full text
PDF![851](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/45268af78e86/aac00026-0259.png)
![852](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/abe5e4561aba/aac00026-0260.png)
![853](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/0012ecb85ca7/aac00026-0261.png)
![854](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/31f6fd258196/aac00026-0262.png)
![855](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/18b392505048/aac00026-0263.png)
![856](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/c6554335a667/aac00026-0264.png)
![857](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/48cfacd0eb50/aac00026-0265.png)
![858](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9cab/187782/4c2eca49bc7d/aac00026-0266.png)
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Akova M., Yang Y., Livermore D. M. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases. J Antimicrob Chemother. 1990 Feb;25(2):199–208. doi: 10.1093/jac/25.2.199. [DOI] [PubMed] [Google Scholar]
- Ambler R. P. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci. 1980 May 16;289(1036):321–331. doi: 10.1098/rstb.1980.0049. [DOI] [PubMed] [Google Scholar]
- Aronoff S. C., Jacobs M. R., Johenning S., Yamabe S. Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin. Antimicrob Agents Chemother. 1984 Oct;26(4):580–582. doi: 10.1128/aac.26.4.580. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bicknell R., Waley S. G. Cryoenzymology of Bacillus cereus beta-lactamase II. Biochemistry. 1985 Nov 19;24(24):6876–6887. doi: 10.1021/bi00345a021. [DOI] [PubMed] [Google Scholar]
- Bonner W. M., Laskey R. A. A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem. 1974 Jul 1;46(1):83–88. doi: 10.1111/j.1432-1033.1974.tb03599.x. [DOI] [PubMed] [Google Scholar]
- Brenner D. G., Knowles J. R. Penicillanic acid sulfone: an unexpected isotope effect in the interaction of 6 alpha- and 6 beta-monodeuterio and of 6,6-dideuterio derivatives with RTEM beta-lactamase from Escherichia coli. Biochemistry. 1981 Jun 23;20(13):3680–3687. doi: 10.1021/bi00516a003. [DOI] [PubMed] [Google Scholar]
- Bush K. Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'. Antimicrob Agents Chemother. 1989 Mar;33(3):264–270. doi: 10.1128/aac.33.3.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bush K. Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4. Antimicrob Agents Chemother. 1989 Mar;33(3):271–276. doi: 10.1128/aac.33.3.271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bush K., Singer S. B. Biochemical characteristics of extended broad spectrum beta-lactamases. Infection. 1989 Nov-Dec;17(6):429–433. doi: 10.1007/BF01645566. [DOI] [PubMed] [Google Scholar]
- Bush K., Singer S. B. Effective cooling allows sonication to be used for liberation of beta-lactamases from gram negative bacteria. J Antimicrob Chemother. 1989 Jul;24(1):82–84. doi: 10.1093/jac/24.1.82. [DOI] [PubMed] [Google Scholar]
- Bush K., Tanaka S. K., Bonner D. P., Sykes R. B. Resistance caused by decreased penetration of beta-lactam antibiotics into Enterobacter cloacae. Antimicrob Agents Chemother. 1985 Apr;27(4):555–560. doi: 10.1128/aac.27.4.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cartwright S. J., Coulson A. F. A semi-synthetic penicillinase inactivator. Nature. 1979 Mar 22;278(5702):360–361. doi: 10.1038/278360a0. [DOI] [PubMed] [Google Scholar]
- Cartwright S. J., Waley S. G. Purification of beta-lactamases by affinity chromatography on phenylboronic acid-agarose. Biochem J. 1984 Jul 15;221(2):505–512. doi: 10.1042/bj2210505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Charnas R. L., Fisher J., Knowles J. R. Chemical studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry. 1978 May 30;17(11):2185–2189. doi: 10.1021/bi00604a025. [DOI] [PubMed] [Google Scholar]
- Chen C. C., Herzberg O. Inhibition of beta-lactamase by clavulanate. Trapped intermediates in cryocrystallographic studies. J Mol Biol. 1992 Apr 20;224(4):1103–1113. doi: 10.1016/0022-2836(92)90472-v. [DOI] [PubMed] [Google Scholar]
- Fass R. J., Prior R. B. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother. 1989 Aug;33(8):1268–1274. doi: 10.1128/aac.33.8.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fisher J., Charnas R. L., Knowles J. R. Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry. 1978 May 30;17(11):2180–2184. doi: 10.1021/bi00604a024. [DOI] [PubMed] [Google Scholar]
- Jaurin B., Grundström T. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of beta-lactamases of the penicillinase type. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4897–4901. doi: 10.1073/pnas.78.8.4897. [DOI] [PMC free article] [PubMed] [Google Scholar]
- KITZ R., WILSON I. B. Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem. 1962 Oct;237:3245–3249. [PubMed] [Google Scholar]
- Kemal C., Knowles J. R. Penicillanic acid sulfone: interaction with RTEM beta-lactamase from Escherichia coli at different pH values. Biochemistry. 1981 Jun 23;20(13):3688–3695. doi: 10.1021/bi00516a004. [DOI] [PubMed] [Google Scholar]
- Kuck N. A., Jacobus N. V., Petersen P. J., Weiss W. J., Testa R. T. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob Agents Chemother. 1989 Nov;33(11):1964–1969. doi: 10.1128/aac.33.11.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- Marunaka T., Maniwa M., Matsushima E., Minami Y. High-performance liquid chromatographic determination of a new beta-lactamase inhibitor and its metabolite in combination therapy with piperacillin in biological materials. J Chromatogr. 1988 Sep 23;431(1):87–101. doi: 10.1016/s0378-4347(00)83072-8. [DOI] [PubMed] [Google Scholar]
- Marunaka T., Matsushima E., Minami Y., Yoshida K., Azuma R. Degradation of beta-lactamase inhibitor, (2S,3R,5S)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-yl-methyl)-4-thi a-1- azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide (YTR-830H), in aqueous solutions and alkaline methanol solution: pathway and structural elucidation of products. Chem Pharm Bull (Tokyo) 1988 Nov;36(11):4478–4487. doi: 10.1248/cpb.36.4478. [DOI] [PubMed] [Google Scholar]
- Mathew A., Harris A. M., Marshall M. J., Ross G. W. The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J Gen Microbiol. 1975 May;88(1):169–178. doi: 10.1099/00221287-88-1-169. [DOI] [PubMed] [Google Scholar]
- Moosdeen F., Williams J. D., Yamabe S. Antibacterial characteristics of YTR 830, a sulfone beta-lactamase inhibitor, compared with those of clavulanic acid and sulbactam. Antimicrob Agents Chemother. 1988 Jun;32(6):925–927. doi: 10.1128/aac.32.6.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Naumovski L., Quinn J. P., Miyashiro D., Patel M., Bush K., Singer S. B., Graves D., Palzkill T., Arvin A. M. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother. 1992 Sep;36(9):1991–1996. doi: 10.1128/aac.36.9.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stefani S., Castiglia P., Maida A., Muresu E., Mezzatesta M. L., Nicoletti G. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. J Chemother. 1990 Oct;2(5):295–299. doi: 10.1080/1120009x.1990.11739032. [DOI] [PubMed] [Google Scholar]
- Yang Y. J., Wu P. J., Livermore D. M. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Antimicrob Agents Chemother. 1990 May;34(5):755–758. doi: 10.1128/aac.34.5.755. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yang Y., Rasmussen B. A., Bush K. Biochemical characterization of the metallo-beta-lactamase CcrA from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother. 1992 May;36(5):1155–1157. doi: 10.1128/aac.36.5.1155. [DOI] [PMC free article] [PubMed] [Google Scholar]